Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. Co. is focused on developing treatments for adult and pediatric cancers. Co.'s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). We show 19 historical shares outstanding datapoints in our QLGN shares outstanding history coverage, used to compute QLGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing QLGN market cap history over the course of time is important for investors
interested in comparing QLGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of QLGN versus a peer is one thing; comparing
QLGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like QLGN can fluctuate over the course of history.
With this page we aim to empower investors researching QLGN by allowing them to research the QLGN market cap history. |
Free QLGN Email Alerts:
Video: The Importance of Market Cap
